Eton Pharmaceuticals Gains FDA Approval for DESMODA Oral Solution

Key Facts

1Eton Pharmaceuticals received U.S. FDA approval for DESMODA™ (desmopressin acetate) Oral Solution.

2The drug is indicated for the management of central diabetes insipidus (AVP-D) for patients of all ages.

3The company's shares are traded on Nasdaq under the ticker ETON.

Eton Pharmaceuticals (ETON) announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application for DESMODA™ Oral Solution. The drug, a formulation of desmopressin acetate, is indicated for the management of central diabetes insipidus (AVP-D) across all age groups. This approval allows the company to offer an antidiuretic replacement therapy in a liquid format, addressing a critical need for patients with arginine vasopressin deficiency. The regulatory milestone follows a rigorous review process and marks a significant step toward commercialization and long-term revenue growth for the Nasdaq-listed firm. Market analysts view this development as a bullish catalyst for ETON shares, given the potential for market expansion in the rare disease sector. The company is now poised to transition from the regulatory phase to active commercial distribution.